ME vs. IMMP, GALT, CDT, ATOS, NKTR, OVID, HOWL, GOSS, QURE, and RIGL
Should you be buying 23andMe stock or one of its competitors? The main competitors of 23andMe include Immutep (IMMP), Galectin Therapeutics (GALT), Conduit Pharmaceuticals (CDT), Atossa Therapeutics (ATOS), Nektar Therapeutics (NKTR), Ovid Therapeutics (OVID), Werewolf Therapeutics (HOWL), Gossamer Bio (GOSS), uniQure (QURE), and Rigel Pharmaceuticals (RIGL). These companies are all part of the "pharmaceutical preparations" industry.
Immutep (NASDAQ:IMMP) and 23andMe (NASDAQ:ME) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, institutional ownership, media sentiment, profitability, dividends, risk, analyst recommendations and community ranking.
Immutep received 297 more outperform votes than 23andMe when rated by MarketBeat users. Likewise, 72.37% of users gave Immutep an outperform vote while only 63.16% of users gave 23andMe an outperform vote.
Immutep has a net margin of 0.00% compared to Immutep's net margin of -210.48%. 23andMe's return on equity of 0.00% beat Immutep's return on equity.
Immutep currently has a consensus target price of $8.50, suggesting a potential upside of 286.36%. 23andMe has a consensus target price of $0.47, suggesting a potential downside of 7.02%. Given 23andMe's stronger consensus rating and higher probable upside, analysts clearly believe Immutep is more favorable than 23andMe.
In the previous week, 23andMe had 18 more articles in the media than Immutep. MarketBeat recorded 22 mentions for 23andMe and 4 mentions for Immutep. 23andMe's average media sentiment score of 0.59 beat Immutep's score of 0.15 indicating that Immutep is being referred to more favorably in the media.
Immutep has a beta of 2.15, suggesting that its stock price is 115% more volatile than the S&P 500. Comparatively, 23andMe has a beta of 1.27, suggesting that its stock price is 27% more volatile than the S&P 500.
2.3% of Immutep shares are owned by institutional investors. Comparatively, 36.1% of 23andMe shares are owned by institutional investors. 3.1% of Immutep shares are owned by company insiders. Comparatively, 27.6% of 23andMe shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Immutep has higher earnings, but lower revenue than 23andMe.
Summary
Immutep beats 23andMe on 12 of the 16 factors compared between the two stocks.
Get 23andMe News Delivered to You Automatically
Sign up to receive the latest news and ratings for ME and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ME and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
